Tag:

venture capital

Latest Headlines

Latest Headlines

Illumina teams with VCs to place $100M bet on consumer genomics

Having played a major role in making consumer genomics feasible, Illumina is now looking to shape how the nascent sector develops. The company has teamed up with big-name VCs to create Helix, a deep-pocketed startup that is one part massive next-generation sequencing operation, one part app store for genomics.

Genalyte ropes in $44M for microchip blood testing system

San Diego's Genalyte reeled in $44 million in a Series C round to spur development of its microchip blood testing platform. The company's Maverick Detection System uses a single drop of blood on a silicon microchip to provide results in 15 minutes, forgoing many of the steps required in traditional blood testing.

WuXi bets $50M on a new venture fund and eyes $200M more

Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.

Asia's emerging biotech scene begs for a look at Kobe, Biocom's Panetta says

Shanghai, Sydney, Singapore, Taipei and Seoul aim to be the biotech hubs in Asia, but San Diego-based CEO of industry group Biocom Joe Panetta said more investors and companies should look hard at Kobe, Japan.

Trialbee raises $5M to mount U.S. expansion of online trial enrollment business

Trialbee has raised $5 million to expand its clinical trial recruitment business in the U.S.

CBMG says China and U.S. growing quickly closer in biotech space

Collaboration between biotech companies from the U.S. and China is in a good state of flux as plays from "friends and family" and signs of growing venture capital and big pharma licensing deals are in motion at the same time, according to Andrew Chan, senior vice president of corporate business development for China only Nasdaq-listed biotech, Cellular Biomedicine Group.

HK-listed Hua Han Bio-Pharmaceutical to raise $400M-plus in open offer

Hong Kong-listed Hua Han Bio-Pharmaceutical Holdings said Wednesday it will raise HK$3.19 billion to HK$3.39 billion ($412 million to $437 million) from an open offer on the basis of one offer share for every two existing shares.

Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says

Chemistry and biology are joining hands in China in ways that will have a profound impact on biotechnology startups and more established companies, but it is still early days for many companies and more money from venture capitalists or other funding sources is welcome.

TrialReach raises $13.5M to connect patients with studies

London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.

Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

U.K. diagnostics outfit Atlas Genetics roped in $20 million in Series C financing to develop its ultrarapid point-of-care tests for infectious diseases, gearing up for a European launch of the product and expanding its foothold in a growing market.